ArticleCell reports2018
OX40 Costimulation Inhibits Foxp3 Expression and Treg Induction via BATF3-Dependent and Independent Mechanisms.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.Frontiers in immunology · 2022Pooled it
- OX40 Ligand/OX40 Axis as the Inflammatory Prequel in Atopic Dermatitis: A Narrative Review.Dermatology and therapy · 2026Review
- Atopic Dermatitis: New Targets and Emerging Systemic Therapies.American journal of clinical dermatology · 2026Review
- The OX40-OX40L Co-Stimulatory Pathway as a Shared Driver of Immune Persistence in Skin and Airway Inflammation.Clinical reviews in allergy & immunology · 2026Review
- The Role of AP-1 in Cancer: Regulation, Tumor Microenvironment and Therapeutic Targeting.Biomolecules · 2026Review
- Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.Cancer cell · 2026Article
- Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026Review
- SRSF3 determines TScience advances · 2026Article
- OX40 signaling in cancer immunotherapy: mechanisms of action, translational applications, and therapeutic perspectives.Frontiers in immunology · 2026Review
- Nuclear receptor coregulator NRIP1 R448G modulates T cell gut homing to control intestinal inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Regulatory T cell and endothelial cell crosstalk.Nature reviews. Immunology · 2025Review
- Sindbis Virus Platform Provides an Oncolytic-Virus-Mediated and Immunotherapeutic Strategy to Overcome the Challenging Microenvironment of Pancreatic Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
- OX40-OX40L Axis in Cutaneous T-Cell Lymphomas: Pathogenic, Prognostic, and Potential Therapeutic Perspectives.Biomolecules · 2025Review
- ACC1 is a dual metabolic-epigenetic regulator of Treg stability and immune tolerance.Molecular metabolism · 2025Article
- Metabolic reprogram and T cell differentiation in inflammation: current evidence and future perspectives.Cell death discovery · 2025Review
- The role of BATF in immune cell differentiation and autoimmune diseases.Biomarker research · 2025Review
- CD137-expressing regulatory T cells in cancer and autoimmune diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment.Journal for immunotherapy of cancer · 2025Article
- The CD8PeerJ · 2025Article
- OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress.Frontiers in oncology · 2025Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Xiaolong ZhangImmunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX, USA.
Xiang XiaoImmunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX, USA.
Peixiang LanImmunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX, USA.
Junhui LiImmunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX, USA.
Yaling DouImmunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX, USA.
Wenhao ChenImmunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX, USA.
Naoto IshiiDepartment of Microbiology and Immunology, Tohoku University, Sendai, Japan.
Shuqiu ChenImmunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX, USA.
Bo XiaDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA.
Kaifu ChenDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA.
Elizabeth TaparowskyDepartment of Biological Sciences, Purdue University, Lafayette, IN, USA.
Xian C LiImmunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX, USA; Department of Surgery, Weill Cornell Medical College of Cornell University, New York, NY, USA. Electronic address: xcli@houstonmethodist.org.
Houston Methodist · USTexas Medical Center · USMethodist Hospital · USPurdue University West Lafayette · USTohoku University · JP
Funding
Control of Treg exhaustion by OX40R01AI106200 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI LI, XIAN CHANG · 2014 to 2025
$4.2MT cell fate decisions and transplant outcomesR01AI129906 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI LI, XIAN CHANG · 2018 to 2022
$1.9MT cell fate decisions and transplant outcomesR56AI129906 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI LI, XIAN CHANG · 2017 to 2017
$402kControl of Treg exhaustion by OX40R56AI106200 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI LI, XIAN CHANG · 2013 to 2013
$276kNIAID NIH HHS R01 AI106200NIAID NIH HHS R01 AI129906NIAID NIH HHS R56 AI106200NIAID NIH HHS R56 AI129906
Abstract
Naive CD4
Indexed as
AcetylationAnimalsBase SequenceBasic-Leucine Zipper Transcription FactorsChromatin Assembly and DisassemblyForkhead Transcription FactorsGenetic LociHistonesMice, TransgenicReceptors, OX40Repressor ProteinsSirtuinsT-Lymphocytes, RegulatoryTOR Serine-Threonine KinasesBasic-Leucine Zipper Transcription FactorsForkhead Transcription FactorsFoxp3 protein, mouseHistonesReceptors, OX40Repressor ProteinsSirtuinsSNFT protein, mouseTnfrsf4 protein, mouseTOR Serine-Threonine KinasesBATF3chromatin remodelingcostimulationFoxp3mTOROX40regulatory T cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.